Cambridge, MA-based gene editing company Editas Medicine (NASDAQ: EDIT) has named Charles Albright its chief scientific officer. Albright was most recently the VP of genetically defined diseases and genomics at Bristol-Myers Squibb, and held positions at Incyte and DuPont Pharmaceuticals before that.
Sponsored · Whitepaper
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson
Sponsored · Webinar
Phenotypic Screening & Profiling to Understand a Compound's Disease Impact
Eurofins Discovery
From Our Editors · Special Report
Becoming the Cell & Gene Therapy Hub
